694 related articles for article (PubMed ID: 21135282)
1. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
[TBL] [Abstract][Full Text] [Related]
2. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Lai A; Filka E; McGibbon B; Nghiemphu PL; Graham C; Yong WH; Mischel P; Liau LM; Bergsneider M; Pope W; Selch M; Cloughesy T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1372-80. PubMed ID: 18355978
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
4. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Lou E; Peters KB; Sumrall AL; Desjardins A; Reardon DA; Lipp ES; Herndon JE; Coan A; Bailey L; Turner S; Friedman HS; Vredenburgh JJ
Cancer Med; 2013 Apr; 2(2):185-95. PubMed ID: 23634286
[TBL] [Abstract][Full Text] [Related]
11. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
[TBL] [Abstract][Full Text] [Related]
12. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Grossman SA; Ye X; Chamberlain M; Mikkelsen T; Batchelor T; Desideri S; Piantadosi S; Fisher J; Fine HA
J Clin Oncol; 2009 Sep; 27(25):4155-61. PubMed ID: 19636006
[TBL] [Abstract][Full Text] [Related]
13. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
15. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
